Latest From Yuhan Corp.
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Infectious & Viral Diseases
- Metabolic Disorders
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Yuhan Corp.
- Senior Management
- Jung Hee Lee, Pres. & CEO
- Contact Info
Phone: 2 828 0181
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.